Biofrontera (NASDAQ:BFRIW – Get Free Report) is expected to be posting its resultson Friday, April 3rd. Analysts expect Biofrontera to post earnings of $0.1950 per share and revenue of $16.1460 million for the quarter.
Biofrontera Stock Performance
Shares of BFRIW stock opened at $0.06 on Thursday. The business has a fifty day moving average of $0.05 and a 200 day moving average of $0.07. Biofrontera has a 1 year low of $0.03 and a 1 year high of $0.28.
About Biofrontera
Biofrontera AG is a biopharmaceutical company headquartered in Leverkusen, Germany, specializing in the development, manufacture and commercialization of dermatology products. Founded in 1997, the company focuses on therapies for skin diseases through innovative drug and device combinations. Its core business centers on photodynamic therapy, where a photosensitizing agent is activated by a specialized light source to treat precancerous and cancerous skin conditions.
The company’s flagship product, Ameluz, is a topical formulation of aminolevulinic acid used in conjunction with the BF-RhodoLED irradiation device.
Featured Stories
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
